We retrospectively analyzed red blood cell (RBC) support and alloimmunization rate in 218 consecutive patients -128 from the Pediatric Department and 90 from the adult Hematology Department -undergoing hematopoietic stem cell transplantation (HSCT) between 1994 and 2000. In the pre-HSCT period, the pediatric patients undergoing auto-HSCT required more RBC support. In the post-HSCT period, pediatric patients transplanted with an unrelated donor required more RBC support (median 13.5 U/10 kg bw) than patients receiving HSCT from a related donor (median 6 U/10 kg bw) or from an autologous source (median 4 U/10 kg bw, P ¼ 0.0004). In the pre-HSCT period, 159 out of 218 patients (73%) received a total of 1843 RBC units, with an overall median of 9 U/patient over a median of 24 months (range 4-62); 10 patients (6%) developed a total of 12 alloantibodies, with an alloimmunization rate of 5.4/1000 RBC units. In the post-HSCT period, all but three patients were given a total of 2420 RBC units, with an overall median of 6 U/ patient over a median of 4 months (range 1-18); all but one of the pre-existing alloantibodies disappeared and three patients (1%) developed new alloantibodies with an alloimmunization rate of 1.2/1000 RBC units. These newly produced alloantibodies (one anti-M and two anti-E) were detected at +58, +90 and +210 days after HSCT. These findings might suggest a different approach to alloantibody screening tests in patients receiving HSCT, with a subsequent reduction of costs and laboratory workload.
Summary:
We retrospectively analyzed red blood cell (RBC) support and alloimmunization rate in 218 consecutive patients -128 from the Pediatric Department and 90 from the adult Hematology Department -undergoing hematopoietic stem cell transplantation (HSCT) between 1994 and 2000. In the pre-HSCT period, the pediatric patients undergoing auto-HSCT required more RBC support. In the post-HSCT period, pediatric patients transplanted with an unrelated donor required more RBC support (median 13.5 U/10 kg bw) than patients receiving HSCT from a related donor (median 6 U/10 kg bw) or from an autologous source (median 4 U/10 kg bw, P ¼ 0.0004). In the pre-HSCT period, 159 out of 218 patients (73%) received a total of 1843 RBC units, with an overall median of 9 U/patient over a median of 24 months (range 4-62); 10 patients (6%) developed a total of 12 alloantibodies, with an alloimmunization rate of 5.4/1000 RBC units. In the post-HSCT period, all but three patients were given a total of 2420 RBC units, with an overall median of 6 U/ patient over a median of 4 months (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ; all but one of the pre-existing alloantibodies disappeared and three patients (1%) developed new alloantibodies with an alloimmunization rate of 1.2/1000 RBC units. These newly produced alloantibodies (one anti-M and two anti-E) were detected at +58, +90 and +210 days after HSCT. These findings might suggest a different approach to alloantibody screening tests in patients receiving HSCT, with a subsequent reduction of costs and laboratory workload. Bone Marrow Transplantation (2003) 32, 231-236. doi:10.1038/sj.bmt.1704114 Keywords: RBC transfusion; alloimmunization; stem cell transplantation Hematopoietic stem cell transplantation (HSCT) has been widely used as a treatment for several oncohematological diseases including acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphomas and solid tumors. 1, 2 Furthermore, HSCT has been proposed as a possible treatment for inherited metabolic storage diseases (IMSD), genetic diseases or severe autoimmune diseases. [3] [4] Autologous (auto) or allogeneic (allo) hematopoietic stem cell (HSC) sources are currently used, the latter having been collected from related (RD) or unrelated (URD) donors, or more recently from cord blood (CB). 5 High-dose chemoradiotherapy administered as conditioning induces prolonged hematopoietic aplasia and immunologic suppression, until engrafment. 6 Patients usually need red blood cell (RBC) transfusion prior to, and especially after, HSCT.
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The amount and frequency of RBC transfusions have been mostly correlated with the patient's age, underlying disease, therapy type of HSCT and post-HSCT complications (ie GvHD, hemorrhagic events, etc) and might be the result of alloimmunization against RBC antigens. 8, 10 Screening tests (which usually have a 3-day validity) aimed at detecting the onset of alloantibodies against erythrocyte antigens are repeatedly performed in patients likely to receive RBC units. This could, in turn, result in an increase in workload and costs, mainly for immunohematology laboratories that support large bone marrow transplantation (BMT) units. Moreover, the collection of multiple blood samples for testing could induce unnecessary RBC loss, particularly in children and low-weight patients. We retrospectively analyzed RBC support and alloimmunization rate against RBC antigens in patients undergoing HSCT at a single institution between January 1994 and June 2000, to investigate the real incidence of alloimmunization against erythrocyte antigens in the post-HSCT period.
Patients and methods

Patients
Clinical and transfusion data regarding all consecutive patients undergoing HSCT in the pediatric and adult BMT units of the San Gerardo Hospital in Monza between January 1994 and June 2000 were recorded. Diagnosis, pre-HSCT RBC support (including the number of transfused units standardized per body weight (bw) and the number of transfusion episodes), type of conditioning regimen, HSC source, HSC manipulation (positive or negative selection), post-HSCT RBC support and date of last transfusion were collected. Complications that could affect RBC requirement, that is, acute GvHD, thrombotic thrombocytopenic purpura (TTP)-like syndrome and CMV infection, were also recorded. Allo-HSCT patients were classified according to ABO (but not Rh) compatibility with the donor. In cases of major or bidirectional ABO-incompatible bone marrow components, RBC were removed by using a COBE Spectra cell separator (Gambro BCT, Lakewood, CO, USA). In the case of minor ABO-incompatible bone marrow components, donor plasma was removed by centrifugation. The ABO group of RBC units transfused to allo-HSCT recipients was determined according to donor and recipient ABO type. Briefly, major incompatible ABO recipients received group O RBC units, and group AB recipients of HSC from a group A or B donor were also given donortype RBC units. Minor incompatible ABO recipients were transfused with group O RBC units, and group A or B recipients from a group AB donor received their own ABO-type RBC units.
Laboratory testing
Until 1996, the screening procedure performed to detect antibodies directed against RBC antigens included a liquid-phase method developed using a three-cell panel (Ortho, Raritan, NJ, USA) at room temperature and 371C, followed by an antiglobulin test, and from 1997, a column gel-test in low-ionic strength medium employing a 0.8% three-cell panel (Diamed, Cressier-sur-Morat, Switzerland). The latter method included enzyme-treated RBC to enhance sensitivity. In the event of a positive screening test, identification of antibodies was accomplished using a commercially available 11-cell panel. The presence of either autoantibodies or cold agglutinin (reactive at 41C) was also recorded. Results of the screening test were considered valid for up to 3 days, and then fresh blood samples were obtained for new screening. In each case a completed cross-match, including a 371C and an antiglobulin step, was performed before an RBC unit was assigned.
Flow cytometry
Flow cytometry analysis was performed using a FACSCalibur instrument (Becton Dickinson, San Diego, CA, USA) equipped with a 560 nm argon laser. CD34+ positive cells were counted in each apheresis or bone marrow yield in both autologous and allogeneic samples to assess the dose of infused stem cells, while CD34+ cells determination on CB units was performed on thawing. An HPCA-2 FITC MoAb directed against CD34 antigen (Becton Dickinson) was used and at least 30 000 events were analyzed in each determination.
Conditioning regimens
Conditioning regimens varied over time in the pediatric and adult setting according to diagnosis and protocols at the time of transplantation. Protocols were classified as TBI or non-TBI containing regimens.
GVHD prophylaxis
According to standard practice, GvHD prophylaxis consisted of cyclosporine (CyA) only in pediatric RD-HSCT recipients and CyA with methotrexate (MTX) in adults. ATG was administered to all URD-HSCT recipients. URD-HSCT grafts in nonmalignant settings and haploidentical grafts were strictly T-cell depleted in vitro by positive CD34+ cells selection and in vivo with ATG. At the onset, acute GvHD was graded according to current criteria. 12 
Transfusion policy
Filtered and irradiated RBC units were administered to maintain the hemoglobin higher than 8 g/dl in asymptomatic patients, that is, in the absence of fever, tachycardia and dyspnea; higher levels were maintained according to clinical requirements. In cases of RD-or URD-HSCT, RBC unit ABO group was selected according to donor and recipient ABO group, as described above. We did not follow the so-called 'perfect match' policy, that is, RBC units were selected regardless of Rh and Kell phenotype, but in the event of Rh discrepancy between donor and recipient (ie D-antigen positive/negative or vice versa), Dnegative RBC units were infused.
HSC manipulation
In some cases, HSC products underwent manipulation both in the autologous setting and in the RD-and URD-HSCT setting, according to adopted protocols. Positive selection was performed by using either the Isolex 300 and the later 300i device (Baxter, Deerfield, IL, USA) with appropriate antibodies, 13 or the CliniMACS Device (Miltenyi Biotec, Bergisch Gladbach, Germany). Negative selection was performed with the SuperMacs Miltenyi apparatus. 14, 15 Engraftment Myeloid engraftment was defined as the first of three consecutive days in which the peripheral blood neutrophil count was 40.5 Â 10 9 /l.
Statistical analysis
RBC support was considered as the number of transfused RBC units/10 kg bw needed to correct for weight disparity. The median number of standardized RBC units in each subgroup of patients was compared with the KruskallWallis test. 16 The number of RBC units/patient was corrected on the basis of recipient body weight expressed as unit/10 kg bw, 8 because the majority of patients in our series was children. All tests were two-sided with a 5% level of significance. The rate of alloimmunization was calculated as the ratio between the number of patients who developed at least one alloantibody and the total number of transfused RBC units, both pre-and post-HSCT.
Results
Overall, 218 consecutive patients (128 in the pediatric and 90 in the adult transplant unit) underwent HSCT at the San Gerardo Hospital in Monza. Table 1 lists patient characteristics and diagnosis: 107 out of the 128 (84%) pediatric patients underwent HSCT for acute leukemia while the majority of adults (59 out of 90, 66%) underwent HSCT for lymphomas (NHL and HD) or multiple myeloma (MM). Allo-HSCT was performed in 93 out of 128 pediatric patients (73%), either from RD (67 patients) or URD (26 patients) and in 11 out of 90 adults from RD only. Nine adults and 51 children received TBI conditioning regimens. Of 104 allo-HSCT, GvHD prophylaxis included CyA (67 patients), CyA+ MTX (23 patients), CyA+ATG (two patients) and CyA+MTX+ATG (12 patients). Major ABO mismatching was present in 28 out of 104 pediatric patients undergoing allo-HSCT (27%).
HSC manipulation
A total of 40 HSC manipulations were performed. In all, 24 negative selections were performed in 10 adults and 14 pediatric patients with ALL, 15 five positive selections were performed in patients with AML (four pediatric patients) and in one adult with MM, six positive selections were performed in children with IMSD, and five double selection (positive/negative) in adults with multiple myeloma.
HSC dose and engraftment
Children who underwent RD-HSCT received more CD34+ cells Â 10 6 /kg compared to adults (P ¼ 0. 6 /kg (range 0.9-32.9). Children who underwent URD-HSCT received 4.4 Â 10 6 /kg (range 0.3-27) CD34+ cells. Myeloid engraftment was achieved at day +11 (range 9-31) in auto-HSCT, and at day +15 (range [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and +19 (range 9-29) in allo-HSCT from RD and URD, respectively. Severe acute GvHD (grade 3-4) developed in 31% of patients undergoing allo-HSCT.
Blood support
The standardized number of RBC units pre-HSCT was significantly higher in the auto-HSCT subgroup, with pediatric patients requiring higher blood support than adult patients: 3 (range 0.2-11) vs 1.3 (range 0.1-7.5) RBC units/10 kg bw (P ¼ 0.007, data not shown).
As to the post-HSCT period (Figure 1 ), only one auto-HSC transplant adult patient and two allo-HSC transplant pediatric patients received no RBC units. Pediatric patients who underwent URD-HSCT required more intensive blood support: median 4.5 RBC units/10 kg bw (range 0.2-40) than those in the auto-HSCT group: median 1 RBC unit/ 10 kg bw (range 0.2-4.6) or those in the RD-HSCT: median 1.7 RBC units/10 kg bw (range 0.2-18) group (P ¼ 0.0004).
Among nonimmunological complications, hemorrhagic cystitis, a TTP-like syndrome and CMV infection/reactivation were analyzed. In pediatric patients, hemorrhagic cystitis was the most frequent complication after URD-(65%) and auto-HSCT (11%), while CMV infection/ reactivation was mostly seen after URD-HSCT (51%). A TTP-like syndrome occurred in 10 patients after URD-HSCT (38%) and in eight after RD-HSCT (12%). In Table 1 Patients' characteristics The box includes all the observations between the first and the third quartile, while the line in bold represents the median. Whiskers extend from the edges of the box to either the extreme values or to a distance of 1.5 Â interquartile range from the median, whichever is less. Data points that fall outside the whiskers are extreme values. *One patient received 40 RBC units/10 kg bw.
adults, CMV infection/reactivation was reported in eight patients after auto-HSCT (10%) and in three patients after RD-HSCT (27%); neither hemorrhagic cystitis nor a TTPlike syndrome were observed. As shown in Table 2 , the need for RBC overall correlated (P ¼ 0.006) with the cumulative number of post-HSCT complications analyzed (mostly due to the larger subgroup of pediatric patients who received RD-HSCT 
Alloimmunization
Without being previously exposed to RBC transfusion, two patients had anti-E and anti-C antibodies which were considered to be naturally occurring. As to the alloimmunization against RBC antigens, 159 out of 218 patients (73%) received a total of 1843 RBC in the pre-HSCT period. In all, 10 of them (6%), receiving a median of 14.5 (range 1-25) RBC units, developed a total of 12 alloantibodies (Table 3) , with an alloimmunization rate of 5.4/1000 RBC units. In the post-HSCT period, a total of 2420 RBC units were administered to 215 patients (99%) and alloantibodies were detected in only three patients (1%) with a rate of 1.2/1000 RBC units. The newly developed alloantibodies (one anti-M and two anti-E) were detected on +58, +90, +210 days after HSCT, respectively. They received 22, 23 and 14 RBC units post-HSCT and only one was given RBC (10 units) before HSCT. Noticeably, all except one (anti-Kell) of the 14 alloantibodies were no longer detectable in the post-HSCT period, even though their carriers received a median of 9.5 (range 2-64) RBC units after transplantation. Overall, a higher median number of typing and screening tests was performed in the post-HSCT period in patients undergoing URD-HSCT compared to RD-HSCT and auto-HSCT patients: median 7 (range 1-36), 4 (range 1-40) and median 3 (1-31), respectively (P ¼ 0.001, data not shown).
Discussion
HSCT has been increasingly adopted as a potentially curative option in several diseases, including hematological malignancies, solid tumors and congenital metabolic abnormalities. [1] [2] [3] [4] High-dose chemotherapy (with or without Table 3 Alloantibody specificity against RBC antigens, pre-and post-HSCT. The patient's diagnosis, type of transplantation, number of RBC transfusions and, only in post-HSCT, day of last RBC transfusion and day of detection of alloantibodies, respectively, are shown in parenthesis. In all, 14 alloantibodies (including two considered as naturally occurring) were detected in 12 patients before HSCT; all but one were not detectable after HSCT; three other patients developed alloantibodies after HSCT. a Naturally occurring alloantibodies. b Enzyme-only reactive antibodies with not-determined specificity. TBI) used as the preparative regimen in both autologous and allogeneic HSCT settings induces prolonged pancytopenia, usually requiring prolonged transfusion support. 5, 6 At the time of transplantation a proportion of patients can have developed alloimmunization against erythrocytes and/ or platelet antigens as a consequence of blood products transfused before HSCT. [7] [8] [9] [10] [11] Furthermore, alloimmunization might occur in the post-HSCT period, as a consequence of the increased blood requirement [9] [10] [11] 17 despite prolonged immunosuppression following HSCT. [18] [19] [20] [21] The first aim of this study was to analyze RBC requirement according to transplant characteristics. In the pretransplant period children undergoing auto-HSCT received more RBC units/10 kg bw than did adults. After HSCT this difference disappeared and our main finding in the post-HSCT period concerned those children who underwent URD-HSCT, who needed more intensive blood support, than did those undergoing RD-HSCT. In fact, 38% of these showed TTP-like clinical features compared to 12% of the children undergoing RD-HSCT, which may in turn account for an increased need for RBC units. 22 Patients undergoing URD-HSCT are more likely to develop higher transplant-related toxicity with severe mucosal gut damage usually resulting in increased bleeding. [23] [24] [25] In our patient series, a higher number of complications did not significantly increase blood support. In fact, the cumulative number of complications did not take into account severity and duration which correlate better with blood requirement. It has been reported 8, 26 that recipients of an HSC graft with minor or major ABO compatibility usually require more RBC units, compared to ABO compatible recipients. However, in our patient series, the number of RBC units administered did not differ in ABO-mismatched recipients, with either minor or major incompatibilities. Similar findings were observed by Rowley et al.
Pre-HSCT
27
As expected, patients who were given URD-HSCT required prolonged blood support, partially explained by patient selection: usually patients eligible for URD-HSCT have resistant disease and therefore had previously received more aggressive treatment, making them eligible for the URD approach, a heavier conditioning regimen and immunosuppression, higher transplant-related toxicity and infectious complications.
The second aim of this study was to determine the alloimmunization rate against RBC antigens in multitransfused immunocompromised patients such as those undergoing HSCT. Immunization against allogeneic RBC antigens is a well-known phenomenon that develops in different patterns depending on patient age and clinical conditions, antigen characteristics and frequency of administration. Alloimmunization rates are lower in young people as well as in the elderly, in the former because of a relative immaturity of the immune system and in the latter because of a poorer efficiency in recognizing allogeneic antigens. Moreover, the time of appearance of a newly formed alloantibody varies from 2 to 24 weeks after stimulation. 28 More than 30% of multitransfused nononcological patients, such as thalassemic patients, develop alloimmunization against foreign RBC antigens, 11 while the alloimmunization rate decreases to 10% in patients with malignancies 7 and to even less than 10% in patients who have undergone intensive chemotherapy. 11 In 1986, Ting et al 17 detected alloantibodies in 8% of 150 patients who were given BMT either from an HLAidentical sibling or an HLA-nonidentical family member. In another more recently published study 10 only 3.7% of 217 patients undergoing allo-HSCT, mostly from an RDdonor, developed alloantibodies against RBC antigens. In the quoted study the mean time between HSCT and antibody detection was 23 days (range 16-672). In our study, we found that 6.3% of transfused patients with a hematological malignancy developed alloantibodies in the pre-HSCT period, with an alloimmunization rate of 5.4/ 1000/transfused units; only 1.4% of patients developed alloantibodies after HSCT, with a four-fold lower alloimmunization rate of 1.2/1000/transfused units. Furthermore, one of the three newly developed alloantibodies, an anti-M detected at day +58, is rarely involved in hemolytic transfusion reactions and is usually considered to have little clinical significance. 29 Differences between previously published studies and the present one can partially be explained by (i) different conditioning mostly in the URD-HSCT setting, (ii) different (and more intensive) immunosuppressive treatment (including ATG) administered as GvHD prophylaxis and (iii) in at least six patients receiving URD-HSCT for inherited metabolic storage diseases, in five patients with multiple myeloma and in five with AML, the use of positively selected CD34+ HSC. Any of the above explanations may have contributed to the reduction in the alloimmunization rate observed in the present study. Moreover, immune reconstitution may be delayed in the post-HSCT course. In the autologous setting, B and T lymphocyte counts can normalize 3-12 months after HSCT, but the CD4/CD8 ratio can remain altered even after the first year. 15, 21 In the allogeneic setting, the period of immunoincompetence can last for up to several years after HSCT, depending on duration of GvHD and immunosuppression. 20, 30 This observation is particularly true in recipients of T-depleted HSCT grafts, where immune recovery is delayed because of a late restoration of thymic activity. 18 Finally, it has been observed that CD4+ T-lymphocytes may not recover completely, for up to as much as 2 years after HSCT, mainly in adults. 19 In conclusion, our findings are similar to those observed by Abou-Elella et al, 31 who detected alloantibodies against RBC antigens in only 2.1% of patients undergoing BMT and suggested that because of the very low incidence of newly produced alloantibodies, screening test validity in patients undergoing HSCT could be extended, resulting in decreased laboratory workload, costs and, lastly, a reduction in the need for patient blood samples. We emphasize that in our patient series, 13 out of 14 alloantibodies detected in the pre-HSCT period disappeared after transplantation, because of chemotherapy and conditioning regimens. The only alloantibody that persisted throughout the HSCT period was an anti-Kell, in a patient who underwent a manipulated (negatively selected) auto-HSCT for ALL. We believe that this patient's conditioning regimen (without TBI) was not completely myeloablative. Furthermore, the three newly detected alloantibodies (two anti-E and one anti-M) were detected +58, +90 and +210 days from HSCT. These findings suggest a more liberal approach in the early post-HSCT period (up to day +45), extending the validity of screening tests (which is usually 3 days) to 5/7 days, at least in patients with an anticipated higher transplant-related toxicity, who are those likely to require more intensive blood support. However, prospective studies are needed before final conclusions regarding the extension of validity of screening tests in the HSCT setting can be drawn.
